IGC Pharma (IGC) Income from Continuing Operations (2010 - 2025)
IGC Pharma (IGC) reported Income from Continuing Operations of 1821000.0 for Q3 2025, down 6.06% year-over-year from 1938411.04 in Q3 2024, and down 13.88% quarter-over-quarter from 1599000.0 in Q2 2025.
IGC Pharma (IGC) Income from Continuing Operations (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of Income from Continuing Operations data on file, last reported at 1821000.0 in Q3 2025.
- Income from Continuing Operations for Q3 2025 came in at 1821000.0, down 6.06% year-over-year; the trailing twelve-month figure through Sep 2025 was 6447000.0 (up 48.71% YoY), and the FY2026 annual result was 2402000.0, up 66.27% from the prior year.
- Income from Continuing Operations slipped to 1821000.0 in Q3 2025 per IGC's latest filing, from 1599000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1198000.0 in Q1 2025 and troughed at 6503000.0 in Q1 2022.
- A 5-year average of 2790157.89 and a median of 2381000.0 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2021 and 2024: Income from Continuing Operations plunged 162.16% in 2021, then jumped 67.28% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 2381000.0 in 2021, then rose by 5.54% to 2249000.0 in 2022, then sank by 148.51% to 5589000.0 in 2023, then jumped by 67.28% to 1829000.0 in 2024, then advanced by 0.44% to 1821000.0 in 2025.
- Business Quant data shows IGC's Income from Continuing Operations at 1821000.0 in Q3 2025, 1599000.0 in Q2 2025, and 1198000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.82 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.20 Mn |
| Dec 31, 2024 | -1.83 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -2.38 Mn |
| Mar 31, 2024 | -2.89 Mn |
| Dec 31, 2023 | -5.59 Mn |
| Sep 30, 2023 | -2.45 Mn |
| Jun 30, 2023 | -2.08 Mn |
| Mar 31, 2023 | -4.03 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.44 Mn |
| Jun 30, 2022 | -2.79 Mn |
| Mar 31, 2022 | -6.50 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -4.34 Mn |
| Jun 30, 2021 | -1.79 Mn |
| Mar 31, 2021 | -2.95 Mn |
| Dec 31, 2020 | -2.32 Mn |